{"_id": "650d0df8c9669d2e208ec2cf", "and": [{"$or": [{"cancer type": "breast cancer"}, {"cancer type": "gastric adenocarcinoma"}, {"cancer type": "gastroesophageal junction adenocarcinoma"}, {"cancer type": "colorectal cancer"}]}, {"$or": [{"HER2 amplification/overexpression": true}, {"uterine serous carcinoma": true}, {"HER2-mutated gastric or gastroesophageal junction adenocarcinoma without HER2-overexpression/amplification": true}]}, {"$and": [{"HER2-directed therapy": {"$ne": true}}, {"hypersensitivity to drug formulation": {"$ne": true}}, {"exposure to cumulative dose of anthracyclines": {"$lt": 360}}]}, {"$not": {"$or": [{"systemic anti-cancer therapy": true}, {"radiation therapy": true}, {"major surgery": true}, {"experimental agent": true}, {"participating in another interventional clinical trial": true}]}}], "nctId": "NCT04579380", "title": "A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations"}